{"url":"https://newsforagent.com/news/2026-11-20/johnson-johnson-tremfya-star-axial-psa","markdown_url":"https://newsforagent.com/news/2026-11-20/johnson-johnson-tremfya-star-axial-psa.md","title":"Johnson & Johnson TREMFYA Shows MRI Axial PsA Gains","headline":"Johnson & Johnson TREMFYA Meets Phase 4 STAR Endpoints in Axial Psoriatic Arthritis","description":"Johnson & Johnson's TREMFYA cut MRI-assessed sacroiliac inflammation more than twice as much as placebo at Week 24 in the Phase 4 STAR study of axial psoriatic arthritis.","section":"Research & Clinical Trials","published_at":"2026-11-20T13:30:43+00:00","modified_at":"2026-11-20T13:30:43+00:00","author":"News Desk","key_takeaways":["TREMFYA reduced SPARCC MRI sacroiliac joint inflammation scores by -7.1 (Q4W) and -5.2 (Q8W) versus -2.4 for placebo at Week 24.","BASDAI scores improved by -3.3 with TREMFYA every four weeks and -2.9 every eight weeks versus -2.1 with placebo.","The Phase 4 STAR study enrolled 411 participants worldwide and is the first dedicated randomized, double-blind, placebo-controlled trial of an IL-23 inhibitor in MRI-confirmed axial PsA."],"companies":[{"name":"Johnson & Johnson Services, Inc.","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00033dv/johnson-johnson-services-inc","website":"https://www.jnj.com"}],"source":{"publisher":"PR Newswire","title":"Johnson & Johnson data in psoriatic arthritis (PsA) shows TREMFYA (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffness","url":"https://www.prnewswire.com/news-releases/johnson--johnson-data-in-psoriatic-arthritis-psa-shows-tremfya-guselkumab-is-the-only-advanced-therapy-to-demonstrate-mri-confirmed-improvements-in-spinal-pain-and-stiffness-302946249.html"},"other_sources":[],"tags":["Research & Clinical Trials","Johnson & Johnson Services, Inc."],"body_markdown":"Johnson & Johnson said on November 20, 2026 that its Phase 4 STAR study of TREMFYA (guselkumab) met primary and major secondary endpoints in biologic-naïve adults with active psoriatic arthritis and axial involvement, with MRI-assessed sacroiliac joint inflammation falling more than twice as much as with placebo at Week 24. The [PR Newswire](https://www.prnewswire.com/news-releases/johnson--johnson-data-in-psoriatic-arthritis-psa-shows-tremfya-guselkumab-is-the-only-advanced-therapy-to-demonstrate-mri-confirmed-improvements-in-spinal-pain-and-stiffness-302946249.html) release carried the late-breaking results, presented at the Emirates Society for Rheumatology Annual Meeting.\n\n## Inside the STAR Trial Results\n\n[Johnson & Johnson Services, Inc.](https://akta.pro/company-profiles/00033dv/johnson-johnson-services-inc) is the New Brunswick-based pharmaceutical and medical-technology group behind TREMFYA, a dual-acting monoclonal antibody that blocks IL-23 and binds to CD64. STAR is a Phase 4, multicenter, randomized, double-blind, placebo-controlled study that enrolled 411 participants worldwide, with a 24-week placebo-controlled period followed by 24 weeks of active treatment.\n\nOn the 10-point BASDAI scale, mean scores improved by -3.3 with TREMFYA 100 mg every four weeks and -2.9 every eight weeks, against -2.1 for placebo at Week 24. ASDAS-CRP fell by -1.5 and -1.3 respectively versus -0.8, exceeding the ≥1.1-unit threshold for clinically important improvement. On the SPARCC MRI score, TREMFYA reduced sacroiliac joint inflammation by -7.1 and -5.2 versus -2.4 for placebo.\n\n\"In the STAR study, TREMFYA showed significant improvements in patient-reported symptoms and MRI-assessed axial inflammation in the sacroiliac joints, backed by a well-characterized safety profile,\" said Prof. Mikkel Ostergaard of the University of Copenhagen and Rigshospitalet. David M. Lee, Johnson & Johnson's Global Immunology Therapeutic Area Head, said the study \"uniquely\" establishes evidence for an IL-23 inhibitor in axial PsA. The company said the overall safety profile was consistent with TREMFYA's established profile in psoriatic disease, with no new safety signals.\n\n## Johnson & Johnson's Deal Record\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Johnson & Johnson completed the $14.6 billion acquisition of Intra-Cellular Therapies in January 2025, expanding its neuroscience and CNS pipeline. The same records show the company acquired Halda Therapeutics for $3.05 billion in November 2025, adding RIPTAC therapies and the HLD-0915 candidate targeting metastatic castration-resistant prostate cancer.\n\n## Earlier Research and Regulatory Steps\n\nOn November 19, 2026, The Motley Fool reported that Johnson & Johnson's JNJ-6143 showed a 75% overall response rate in a Phase 1 trial for metastatic castration-resistant prostate cancer at ESMO 2026. The same day, PR Newswire reported that Johnson & Johnson submitted a supplemental NDA to the FDA for CAPLYTA to treat manic or mixed episodes in bipolar I disorder, supported by two Phase 3 studies showing significant symptom reduction versus placebo as early as Day 3.\n\n## What Comes Next for TREMFYA\n\nThe STAR results are scheduled for presentation at the Emirates Society for Rheumatology Annual Meeting in Dubai, United Arab Emirates, running November 20-22, 2026. TREMFYA is not approved for every-four-weeks dosing in the U.S., and the company's release lists no filing date for an axial PsA label update.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}